ArticleAntioxidants (Basel, Switzerland)2025
Antioxidant Activity of Bovine Colostrum in the Colon of a Mouse Model of TNBS-Induced Colitis.
Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short-term high-altitude exposure protects working memory by balancing intestinal microbiota.BMC microbiology · 2026Article
- Clinical Applications of Bovine Colostrum in GastrointestinaI Disorders: Mechanisms, Evidence, and Therapeutic Potential.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Bovine colostrum (BC) is the initial milk produced by cows after giving birth and has revealed significant potential in helping various health conditions, particularly in diseases of the gastrointestinal tract, such as inflammatory bowel disease, including colitis. BC is renowned for its rich composition of components that strengthen the immune system. Inflammatory bowel diseases, including colitis, are characterized by elevated oxidative stress, leading to tissue damage and exacerbated symptoms. The aim of this study was to explore the potential antioxidant activity of bovine colostrum in the context of a mouse model of trinitrobenzene sulfonic acid-induced colitis. The effectiveness of BC in mitigating oxidative stress and its effects on colitis was evaluated. (2) Methods: Mice were divided into two groups, one group received BC by gavage for 21 days, the other group received saline solution; after 21 days one half of each of the two groups of mice were treated intrarectally with trinitrobenzene sulfonic acid to induce colitis. Colon samples were processed by immunocytochemical methods. The immunoreactivity of the main antioxidant enzymes, (i) catalase (CAT), (ii) superoxide dismutase 1 (SOD1), (iii) superoxide dismutase 2 (SOD2) and glutathione peroxidase 4 (GPX4), at the colon level was analyzed. (3) Results: The results showed positive immunoreactivity of catalase and SOD2 activities of BC in the colon of animals after induction of inflammation. (4) Conclusions: The findings have the potential to suggest new strategies for the management of gastrointestinal disorders related to oxidative stress. Furthermore, the knowledge gained could contribute to the development of functional foods or supplements specifically designed for the management of colitis. Future studies will be aimed at identifying the bioactive fractions of BC to study the mechanisms underlying its actions, as well as to trace which populations can benefit most from colostrum consumption, in addition to subjects with gastrointestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.